NASDAQ:GBT - Global Blood Therapeutics Stock Price, Price Target & More

$46.00 +1.40 (+3.14 %)
(As of 04/27/2018 04:48 AM ET)
Previous Close$44.60
Today's Range$44.80 - $46.30
52-Week Range$24.02 - $68.05
Volume637,400 shs
Average Volume997,013 shs
Market Capitalization$2.19 billion
P/E Ratio-16.67
Dividend YieldN/A
Beta4.37

About Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics logoGlobal Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its lead product candidate is voxelotor, an oral once-daily therapy that modulates hemoglobin's affinity for oxygen, which is in Phase III clinical trials in adult and adolescent patients with sickle cell disease (SCD). The company is also involved in evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trials of adolescent and pediatric patients with SCD; and other research and development activities that are in pre-clinical phase. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.

Receive GBT News and Ratings via Email

Sign-up to receive the latest news and ratings for GBT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GBT
CUSIPN/A
Phone650-741-7700

Debt

Debt-to-Equity RatioN/A
Current Ratio12.35%
Quick Ratio12.35%

Price-To-Earnings

Trailing P/E Ratio-16.67
Forward P/E Ratio-12.17
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$6.93 per share
Price / Book6.64

Profitability

EPS (Most Recent Fiscal Year)($2.76)
Net Income$-117,020,000.00
Net MarginsN/A
Return on Equity-40.31%
Return on Assets-37.14%

Miscellaneous

Employees147
Outstanding Shares50,730,000

Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics (NASDAQ:GBT) posted its earnings results on Tuesday, February, 27th. The company reported ($0.94) earnings per share for the quarter, missing analysts' consensus estimates of ($0.72) by $0.22. View Global Blood Therapeutics' Earnings History.

When is Global Blood Therapeutics' next earnings date?

Global Blood Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April, 30th 2018. View Earnings Estimates for Global Blood Therapeutics.

What price target have analysts set for GBT?

12 brokers have issued 1-year target prices for Global Blood Therapeutics' stock. Their forecasts range from $46.00 to $91.00. On average, they anticipate Global Blood Therapeutics' stock price to reach $73.5833 in the next twelve months. View Analyst Ratings for Global Blood Therapeutics.

What are Wall Street analysts saying about Global Blood Therapeutics stock?

Here are some recent quotes from research analysts about Global Blood Therapeutics stock:
  • 1. Needham & Company LLC analysts commented, "Here we review our expectations for Part A of the HOPE trial which includes survey findings from 36 sickle cell disease (SCD) experts. We believe there is more than one path forward for voxelotor, but we think upside potential could vary significantly based on Part A findings. If reported Part A outcomes meet expectations as defined below, we think the stock could easily return to the $70 level (+60%) it was trading at in January." (4/26/2018)
  • 2. According to Zacks Investment Research, "Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. " (3/6/2018)
  • 3. Cantor Fitzgerald analysts commented, "At ASH, Global Blood announced multi-dose Phase 2a data with voxelotor (GBT440), in adolescent (ages 12-17) patients." (12/11/2017)
  • 4. Cowen Inc analysts commented, "GBT reported Q3 earnings last week and provided a brief summary of their progress." (11/9/2017)

Who are some of Global Blood Therapeutics' key competitors?

Who are Global Blood Therapeutics' key executives?

Global Blood Therapeutics' management team includes the folowing people:
  • Dr. Ted W. Love, Pres, CEO & Director (Age 59)
  • Dr. Charles J. Homcy, Founder, Advisor & Director (Age 70)
  • Mr. Jeffrey S. Farrow, Chief Financial Officer (Age 56)
  • Ms. Tricia Borga Suvari Esq., Chief Legal Officer and Sec. (Age 57)
  • Dr. David R. Phillips Ph.D., Founder and Advisor

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an initial public offering (IPO) on Wednesday, August 12th 2015. The company issued 6,000,000 shares at $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

Has Global Blood Therapeutics been receiving favorable news coverage?

News articles about GBT stock have been trending somewhat positive on Friday, Accern reports. The research group identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Global Blood Therapeutics earned a news impact score of 0.15 on Accern's scale. They also gave news stories about the company an impact score of 45.91 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Global Blood Therapeutics?

Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Global Blood Therapeutics' stock price today?

One share of GBT stock can currently be purchased for approximately $46.00.

How big of a company is Global Blood Therapeutics?

Global Blood Therapeutics has a market capitalization of $2.19 billion. The company earns $-117,020,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis. Global Blood Therapeutics employs 147 workers across the globe.

How can I contact Global Blood Therapeutics?

Global Blood Therapeutics' mailing address is 171 OYSTER POINT BOULEVARD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at i[email protected]


MarketBeat Community Rating for Global Blood Therapeutics (GBT)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  275 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  413
MarketBeat's community ratings are surveys of what our community members think about Global Blood Therapeutics and other stocks. Vote "Outperform" if you believe GBT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GBT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Global Blood Therapeutics (NASDAQ:GBT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
12 Wall Street analysts have issued ratings and price targets for Global Blood Therapeutics in the last 12 months. Their average twelve-month price target is $73.5833, suggesting that the stock has a possible upside of 59.96%. The high price target for GBT is $91.00 and the low price target for GBT is $46.00. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.922.923.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $73.5833$73.5833$65.2143$55.7273
Price Target Upside: 59.96% upside38.84% upside15.73% upside73.34% upside

Global Blood Therapeutics (NASDAQ:GBT) Consensus Price Target History

Price Target History for Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics (NASDAQ:GBT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/26/2018Needham & Company LLCReiterated RatingBuy$70.00HighView Rating Details
3/21/2018Morgan StanleyDowngradeOverweight -> Equal Weight$61.00HighView Rating Details
3/14/2018WedbushReiterated RatingOutperform$73.00LowView Rating Details
3/12/2018HC WainwrightSet Price TargetBuy$73.00HighView Rating Details
3/1/2018SunTrust BanksSet Price TargetPositive -> Buy$80.00MediumView Rating Details
2/28/2018William BlairReiterated RatingBuyHighView Rating Details
2/27/2018Cantor FitzgeraldSet Price TargetOverweight -> Overweight$61.00 -> $72.00HighView Rating Details
2/13/2018Janney Montgomery ScottInitiated CoverageBuy -> Buy$75.00MediumView Rating Details
12/12/2017OppenheimerSet Price TargetBuy$53.00 -> $79.00HighView Rating Details
12/11/2017NomuraBoost Price TargetBuy$91.00HighView Rating Details
11/9/2017CowenReiterated RatingBuy$83.00N/AView Rating Details
10/23/2017JPMorgan ChaseReiterated RatingBuyN/AView Rating Details
3/20/2017Roth CapitalSet Price TargetBuy$47.00LowView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$50.00N/AView Rating Details
9/30/2016Wells FargoInitiated CoverageOutperform$75.00 -> $23.05N/AView Rating Details
(Data available from 4/27/2016 forward)

Earnings

Global Blood Therapeutics (NASDAQ:GBT) Earnings History and Estimates Chart

Earnings by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics (NASDAQ:GBT) Earnings Estimates

2018 EPS Consensus Estimate: ($3.86)
2019 EPS Consensus Estimate: ($4.36)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.94)($0.89)($0.91)
Q2 20183($0.99)($0.92)($0.95)
Q3 20183($1.03)($0.94)($0.98)
Q4 20183($1.08)($0.97)($1.01)
Q1 20192($1.08)($1.03)($1.06)
Q2 20192($1.11)($1.08)($1.10)
Q3 20192($1.12)($1.04)($1.08)
Q4 20192($1.18)($1.07)($1.13)

Global Blood Therapeutics (NASDAQ GBT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/30/2018($0.91)N/AView Earnings Details
2/27/2018Q4 2017($0.7180)($0.94)ViewN/AView Earnings Details
11/2/2017Q3 2017($0.62)($0.66)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.61)($0.55)ViewN/AView Earnings Details
5/1/2017Q1 2017($0.71)($0.60)ViewN/AView Earnings Details
3/13/2017Q4 2016($0.64)($0.74)ViewN/AView Earnings Details
11/9/2016Q316($0.58)($0.58)ViewN/AView Earnings Details
8/10/2016Q216($0.63)($0.58)ViewN/AView Earnings Details
5/12/2016Q1($0.48)($0.56)ViewN/AView Earnings Details
3/29/2016Q4($0.6350)($0.53)ViewN/AView Earnings Details
11/12/2015Q3 2015($0.71)($0.90)ViewN/AView Earnings Details
9/24/2015Q2 2015($4.04)($4.84)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Global Blood Therapeutics (NASDAQ:GBT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Global Blood Therapeutics (NASDAQ GBT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 85.45%
Insider Trading History for Global Blood Therapeutics (NASDAQ:GBT)
Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics (NASDAQ GBT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/17/2018Jung ChoiInsiderSell3,000$45.50$136,500.00137,677View SEC Filing  
3/16/2018Jung ChoiInsiderSell3,000$54.15$162,450.00139,277View SEC Filing  
3/5/2018Lesley Ann CalhounInsiderSell99$60.35$5,974.65View SEC Filing  
2/16/2018Jung ChoiInsiderSell3,000$62.95$188,850.00140,877View SEC Filing  
2/1/2018Peter RadovichInsiderSell812$57.30$46,527.606,221View SEC Filing  
1/23/2018Peter RadovichInsiderSell30,000$60.00$1,800,000.0033,581View SEC Filing  
1/17/2018Jung ChoiInsiderSell3,000$52.85$158,550.00137,255View SEC Filing  
1/10/2018Peter RadovichInsiderSell15,000$50.00$750,000.0017,684View SEC Filing  
12/19/2017Perceptive Advisors LlcMajor ShareholderBuy175,000$38.00$6,650,000.00View SEC Filing  
12/18/2017Jung ChoiInsiderSell3,000$36.55$109,650.00135,255View SEC Filing  
10/30/2017Peter RadovichVPSell12,500$35.00$437,500.002,684View SEC Filing  
10/27/2017Charles J HomcyDirectorSell70,000$33.97$2,377,900.0083,328View SEC Filing  
10/17/2017Jung ChoiInsiderSell3,000$32.65$97,950.00138,455View SEC Filing  
9/29/2017Jung ChoiInsiderSell3,000$30.00$90,000.00140,055View SEC Filing  
8/31/2017Jung ChoiInsiderSell3,000$30.00$90,000.00141,655View SEC Filing  
7/25/2017Deval L PatrickDirectorSell27,053$29.69$803,203.5712,053View SEC Filing  
7/21/2017Jung ChoiInsiderSell3,000$30.00$90,000.00143,255View SEC Filing  
4/6/2017Robert I TepperMajor ShareholderSell31,225$33.23$1,037,606.75229,773View SEC Filing  
12/16/2016Kevin P StarrMajor ShareholderSell108,955$16.00$1,743,280.0082,544View SEC Filing  
1/7/2016John SchembriinsiderBuy1,500$21.57$32,355.001,500View SEC Filing  
12/22/2015Eleanor RamosinsiderBuy11,000$20.93$230,230.0011,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Global Blood Therapeutics (NASDAQ GBT) News Headlines

Source:
DateHeadline
Zacks: Brokerages Anticipate Global Blood Therapeutics (GBT) to Announce -$0.92 EPSZacks: Brokerages Anticipate Global Blood Therapeutics (GBT) to Announce -$0.92 EPS
www.americanbankingnews.com - April 27 at 1:26 AM
Needham & Company LLC Reiterates Buy Rating for Global Blood Therapeutics (GBT)Needham & Company LLC Reiterates Buy Rating for Global Blood Therapeutics (GBT)
www.americanbankingnews.com - April 26 at 4:22 PM
Global Blood Therapeutics (GBT) to Release Quarterly Earnings on MondayGlobal Blood Therapeutics (GBT) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 23 at 8:26 AM
Global Blood Therapeutics (GBT) Receives Average Rating of "Buy" from AnalystsGlobal Blood Therapeutics (GBT) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 22 at 5:34 PM
Global Blood Therapeutics Inc (GBT) Insider Jung Choi Sells 3,000 SharesGlobal Blood Therapeutics Inc (GBT) Insider Jung Choi Sells 3,000 Shares
www.americanbankingnews.com - April 19 at 7:36 PM
Global Blood Therapeutics (GBT) Rating Reiterated by JPMorgan ChaseGlobal Blood Therapeutics (GBT) Rating Reiterated by JPMorgan Chase
www.americanbankingnews.com - April 12 at 7:57 PM
Global Blood Therapeutics (GBT) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowGlobal Blood Therapeutics (GBT) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 11 at 4:57 PM
-$0.91 EPS Expected for Global Blood Therapeutics Inc (GBT) This Quarter-$0.91 EPS Expected for Global Blood Therapeutics Inc (GBT) This Quarter
www.americanbankingnews.com - April 10 at 3:10 AM
Zacks Investment Research Upgrades Global Blood Therapeutics (GBT) to BuyZacks Investment Research Upgrades Global Blood Therapeutics (GBT) to Buy
www.americanbankingnews.com - April 7 at 3:52 PM
Global Blood Therapeutics (GBT) Cut to Sell at BidaskClubGlobal Blood Therapeutics (GBT) Cut to Sell at BidaskClub
www.americanbankingnews.com - April 5 at 10:33 AM
Oppenheimer Reiterates "$53.00" Price Target for Global Blood Therapeutics (GBT)Oppenheimer Reiterates "$53.00" Price Target for Global Blood Therapeutics (GBT)
www.americanbankingnews.com - April 4 at 2:58 PM
GBT Announces Participation at the H.C. Wainwright Global Life Sciences ConferenceGBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - April 3 at 4:56 PM
Global Blood Therapeutics (GBT) Rating Increased to Buy at ValuEngineGlobal Blood Therapeutics (GBT) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 3:36 PM
Global Blood Therapeutics (GBT) Upgraded to "Buy" by BidaskClubGlobal Blood Therapeutics (GBT) Upgraded to "Buy" by BidaskClub
www.americanbankingnews.com - April 2 at 6:26 PM
Global Blood Therapeutics (GBT) Cut to "Sell" at Zacks Investment ResearchGlobal Blood Therapeutics (GBT) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 1 at 2:38 PM
Global Blood Therapeutics (GBT) PT Set at $73.00 by HC WainwrightGlobal Blood Therapeutics (GBT) PT Set at $73.00 by HC Wainwright
www.americanbankingnews.com - March 28 at 8:42 PM
Global Blood Therapeutics Inc (GBT) Receives Consensus Rating of "Buy" from BrokeragesGlobal Blood Therapeutics Inc (GBT) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 28 at 5:40 PM
William Blair Initiates Coverage on Global Blood Therapeutics (GBT)William Blair Initiates Coverage on Global Blood Therapeutics (GBT)
www.americanbankingnews.com - March 26 at 7:41 PM
Global Blood Therapeutics (GBT) Upgraded at ValuEngineGlobal Blood Therapeutics (GBT) Upgraded at ValuEngine
www.americanbankingnews.com - March 25 at 5:52 PM
Cantor Fitzgerald Analysts Give Global Blood Therapeutics (GBT) a $72.00 Price TargetCantor Fitzgerald Analysts Give Global Blood Therapeutics (GBT) a $72.00 Price Target
www.americanbankingnews.com - March 24 at 5:43 PM
Global Blood Therapeutics (GBT) Given a $80.00 Price Target at SunTrust BanksGlobal Blood Therapeutics (GBT) Given a $80.00 Price Target at SunTrust Banks
www.americanbankingnews.com - March 24 at 2:13 PM
 Brokerages Expect Global Blood Therapeutics Inc (GBT) to Post -$0.91 EPS Brokerages Expect Global Blood Therapeutics Inc (GBT) to Post -$0.91 EPS
www.americanbankingnews.com - March 24 at 3:17 AM
Morgan Stanley Lowers Global Blood Therapeutics (GBT) to Equal WeightMorgan Stanley Lowers Global Blood Therapeutics (GBT) to Equal Weight
www.americanbankingnews.com - March 21 at 6:40 PM
Insider Selling: Global Blood Therapeutics Inc (GBT) Insider Sells 3,000 Shares of StockInsider Selling: Global Blood Therapeutics Inc (GBT) Insider Sells 3,000 Shares of Stock
www.americanbankingnews.com - March 20 at 8:10 PM
Equities Analysts Set Expectations for Global Blood Therapeutics Incs Q1 2018 Earnings (GBT)Equities Analysts Set Expectations for Global Blood Therapeutics Inc's Q1 2018 Earnings (GBT)
www.americanbankingnews.com - March 19 at 1:40 AM
GBT Announces New Employment Inducement Grants - GlobeNewswire (press release)GBT Announces New Employment Inducement Grants - GlobeNewswire (press release)
globenewswire.com - March 16 at 5:20 PM
GBT Announces New Employment Inducement GrantsGBT Announces New Employment Inducement Grants
finance.yahoo.com - March 15 at 5:04 PM
Global Blood Therapeutics (GBT) Receives "Outperform" Rating from WedbushGlobal Blood Therapeutics (GBT) Receives "Outperform" Rating from Wedbush
www.americanbankingnews.com - March 14 at 3:15 PM
Global Blood Therapeutics Announces Full Exercise of Underwriter’s Option to Purchase Additional SharesGlobal Blood Therapeutics Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares
finance.yahoo.com - March 12 at 5:04 PM
Global Blood Therapeutics (GBT) Rating Lowered to Hold at BidaskClubGlobal Blood Therapeutics (GBT) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - March 10 at 4:33 PM
Why Now Seems Like the Best Time for a Global Blood Therapeutics Secondary OfferingWhy Now Seems Like the Best Time for a Global Blood Therapeutics Secondary Offering
www.msn.com - March 9 at 5:18 PM
Is Global Blood Therapeutics Inc’s (NASDAQ:GBT) Liquidity As Good As Its Solvency?Is Global Blood Therapeutics Inc’s (NASDAQ:GBT) Liquidity As Good As Its Solvency?
finance.yahoo.com - March 9 at 10:18 AM
Global Blood Therapeutics (GBT) Downgraded by Zacks Investment ResearchGlobal Blood Therapeutics (GBT) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 7 at 12:34 AM
Global Blood Therapeutics (GBT) Given New $61.00 Price Target at Morgan StanleyGlobal Blood Therapeutics (GBT) Given New $61.00 Price Target at Morgan Stanley
www.americanbankingnews.com - March 6 at 11:00 AM
GBT Appoints Industry Leader David L. Johnson as Chief Commercial OfficerGBT Appoints Industry Leader David L. Johnson as Chief Commercial Officer
finance.yahoo.com - March 6 at 9:11 AM
Sectoral Asset Management Inc Sells 91,940 Shares of Global Blood Therapeutics Inc (GBT)Sectoral Asset Management Inc Sells 91,940 Shares of Global Blood Therapeutics Inc (GBT)
www.americanbankingnews.com - March 5 at 3:35 PM
FY2018 EPS Estimates for Global Blood Therapeutics Inc Reduced by Analyst (GBT)FY2018 EPS Estimates for Global Blood Therapeutics Inc Reduced by Analyst (GBT)
www.americanbankingnews.com - March 5 at 5:57 AM
Global Blood Therapeutics (GBT) Scheduled to Post Earnings on MondayGlobal Blood Therapeutics (GBT) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - March 5 at 2:16 AM
Emory University Trims Holdings in Global Blood Therapeutics Inc (GBT)Emory University Trims Holdings in Global Blood Therapeutics Inc (GBT)
www.americanbankingnews.com - March 4 at 2:59 PM
Global Blood Therapeutics (GBT) Cut to Buy at BidaskClubGlobal Blood Therapeutics (GBT) Cut to Buy at BidaskClub
www.americanbankingnews.com - March 3 at 11:42 PM
Global Blood Therapeutics Inc (GBT) Receives Average Rating of "Buy" from AnalystsGlobal Blood Therapeutics Inc (GBT) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 3 at 5:56 PM
EAM Investors LLC Sells 23,501 Shares of Global Blood Therapeutics Inc (GBT)EAM Investors LLC Sells 23,501 Shares of Global Blood Therapeutics Inc (GBT)
www.americanbankingnews.com - March 3 at 5:40 AM
Global Blood Therapeutics Inc (GBT) to Post Q1 2018 Earnings of ($0.90) Per Share, Oppenheimer ForecastsGlobal Blood Therapeutics Inc (GBT) to Post Q1 2018 Earnings of ($0.90) Per Share, Oppenheimer Forecasts
www.americanbankingnews.com - March 2 at 9:30 AM
Analysts Offer Predictions for Global Blood Therapeutics Incs Q1 2018 Earnings (GBT)Analysts Offer Predictions for Global Blood Therapeutics Inc's Q1 2018 Earnings (GBT)
www.americanbankingnews.com - March 2 at 9:30 AM
Global Blood Therapeutics (GBT) Releases  Earnings Results, Misses Expectations By $0.22 EPSGlobal Blood Therapeutics (GBT) Releases Earnings Results, Misses Expectations By $0.22 EPS
www.americanbankingnews.com - March 1 at 11:06 AM
Global Blood Therapeutics (GBT) Given a $73.00 Price Target by HC Wainwright AnalystsGlobal Blood Therapeutics (GBT) Given a $73.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - February 28 at 6:54 PM
Global Blood Therapeutics (GBT) Receives "Buy" Rating from William BlairGlobal Blood Therapeutics (GBT) Receives "Buy" Rating from William Blair
www.americanbankingnews.com - February 28 at 6:54 PM
GBT Reports Recent Business Progress and Fourth Quarter and Year-End 2017 Financial ResultsGBT Reports Recent Business Progress and Fourth Quarter and Year-End 2017 Financial Results
finance.yahoo.com - February 27 at 5:06 PM
51,301 Shares in Global Blood Therapeutics Inc (GBT) Purchased by Stansberry Asset Management LLC51,301 Shares in Global Blood Therapeutics Inc (GBT) Purchased by Stansberry Asset Management LLC
www.americanbankingnews.com - February 27 at 2:15 PM
Global Blood Therapeutics Inc (GBT) Insider Sells $188,850.00 in StockGlobal Blood Therapeutics Inc (GBT) Insider Sells $188,850.00 in Stock
www.americanbankingnews.com - February 21 at 9:24 PM

SEC Filings

Global Blood Therapeutics (NASDAQ:GBT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Global Blood Therapeutics (NASDAQ:GBT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Global Blood Therapeutics (NASDAQ GBT) Stock Chart for Friday, April, 27, 2018

Loading chart…

This page was last updated on 4/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.